Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Hemagglutinin antigen of Influenza B virus** is a trimeric viral surface glycoprotein that mediates the virus’s entry into host cells. HA binds to sialic acid-containing receptors on the host cell surface, determining viral attachment and host specificity[1][2][4][5][6]. After receptor binding, HA undergoes a pH-triggered conformational change that drives the fusion of the viral envelope with the endosomal membrane, allowing genomic entry[1][2][5][6]. It is the major antigenic determinant of the Influenza B virus, being the principal target of neutralizing antibodies and the primary component evaluated in seasonal influenza vaccines[5][6]. HA structural variability underlies both susceptibility to immune recognition (hence the efficacy of vaccines and antibodies) and the antigenic drift that necessitates frequent vaccine updates[3][5][6]. Because of its essential role in infection and immunogenicity, HA is a leading therapeutic and diagnostic target in influenza research and public health[4][5][6]. **Notes:** - No small-molecule drugs directly target HA in Influenza B infection; anti-HA monoclonal antibodies are an area of research, and vaccines are the main interacting interventions. - "Hemagglutinin" can refer to analogous proteins in other viruses (such as Influenza A), but structure, sequence, and immunogenicity may differ substantially between types[2][3]. - For structural and epitope details, the HA from Influenza B shows about 25% sequence identity with that of Influenza A, though domain organization is conserved[3][2]. - The standard functional assays for anti-HA immunity include the hemagglutination inhibition assay[5]. If more specificity is needed (e.g., strain/subtype context), include the appropriate strain name or subtype.
Neutralizing antibodies bind HA, blocking receptor binding or fusion; Vaccines induce antibodies targeting HA to prevent infection
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin antigen of Influenza B virus (HA).